The estimated Net Worth of Raju S.K. Chaganti is at least $1.78 million dollars as of 25 June 2015. Raju Chaganti owns over 5,296 units of Cancer Genetics stock worth over $774,281 and over the last 12 years Raju sold CGIX stock worth over $1,002,197.
Sign up
Raju Chaganti CGIX stock SEC Form 4 insiders trading
Raju has made over 4 trades of the Cancer Genetics stock since 2015, according to the Form 4 filled with the SEC. Most recently Raju sold 5,296 units of CGIX stock worth $63,552 on 25 June 2015.
The largest trade Raju's ever made was selling 46,454 units of Cancer Genetics stock on 9 June 2015 worth over $558,842. On average, Raju trades about 7,576 units every 2 days since 2013. As of 25 June 2015 Raju still owns at least 171,681 units of Cancer Genetics stock.
You can see the complete history of Raju Chaganti stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Raju Chaganti's mailing address?
Raju's mailing address filed with the SEC is 201 ROUTE 17 NORTH, 2ND FLOOR, , RUTHERFORD, NJ, 07070.
Insiders trading at Cancer Genetics
Over the last 12 years, insiders at Cancer Genetics have traded over $1,720,897 worth of Cancer Genetics stock and bought 3,891,559 units worth $4,573,241 . The most active insiders traders include John Pappajohn, Tommy G Thompson et John A Roberts. On average, Cancer Genetics executives and independent directors trade stock every 35 days with the average trade being worth of $340,207. The most recent stock trade was executed by John A Roberts on 31 January 2019, trading 185,436 units of CGIX stock currently worth $42,650.
What does Cancer Genetics's logo look like?
Complete history of Raju Chaganti stock trades at Cancer Genetics
Cancer Genetics executives and stock owners
Cancer Genetics executives and other stock owners filed with the SEC include:
-
Jane Houldsworth,
Vice President - Research & Development -
Franklyn Prendergast,
Independent Director -
Howard McLeod,
Independent Director -
Edmund Cannon,
Independent Director -
Thomas Widmann,
Director -
Geoffrey Harris,
Director -
John Roberts,
President, Chief Executive Officer, Principal Financial Officer and Principal Accounting Officer -
John Pappajohn,
Non-Executive Chairman of the Board -
Panna Sharma,
Chief Executive Officer -
Raju S.K. Chaganti,
Director -
Michael J. Welsh,
Director -
Edward J Sitar,
Chief Financial Officer -
Igor Gitelman,
Chief Accounting Officer -
Michael Brian Mc Cartney,
Chief Commercial Officer -
Michael Glenn Miles,
Chief Financial Officer -
Ralf Brandt,
President, Discovery Services -
Rita Shaknovich,
VP of Hematopathology Services -
Paul Rothman,
Director -
Keith L Brownlie,
Director -
Andrew L Pecora,
Director -
Tommy G Thompson,
Director -
Steven Hepburn,
VP of Biopharma Marketing